We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
1
1.Alvir, JM, Lieberman, JA. A revaluation of the clinical characteristics of Clozapine-induced agranulocytosis in light of the United States experience. J Clin Psychopharmacol1994; 14, lex 2501:87–9.Google Scholar
2
2.Meltzer, HY, Cola, P, Way, L, Thompson, PA, Bastani, B, Davies, MA, Snitz, B. Cost effectiveness of Clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry1993; 150;11:1630–83.Google ScholarPubMed
3
3.Murdock, PS , Williamson, J. A danger in making the diagnosis of Parkinson's disease. Lancet1982; 2:1212–3.CrossRefGoogle Scholar
4
4.Cassano, GB, Castrogiovanni, P, Conti, L. Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial. CurrTherRes1975; 17: 189–201.Google ScholarPubMed
5
5.Gerlach, J, Behnke, K, Heltberg, J, et al.Sulpride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br J Psychiatry1985; 147: 283–8.CrossRefGoogle Scholar
6
6.Friefman, JH. The management of the levodopa psychoses. Clin Neuropharmacol1991;14:283–95.CrossRefGoogle Scholar
7
7.Alberts, JL, Francois, F, Josserand, F. Study of side effects reported in patients under dogmatil (in french). Sem Hop1985; 61: 1351–7.Google Scholar